FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer
For patients with metastatic hormone-sensitive prostate cancer (HSPC), a supplemental new drug application (sNDA) for the oral androgen receptor (AR) inhibitor darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) has been accepted …